<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820439</url>
  </required_header>
  <id_info>
    <org_study_id>HS627-BE</org_study_id>
    <nct_id>NCT04820439</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection</brief_title>
  <official_title>Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection (HS627) and Perjeta ® in Healthy Male Subjects: a Randomized, Double-blind, Parallelity-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of Qingdao University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed as a randomized, double-blind, parallelity-controlled&#xD;
      study.Eighty-eight healthy male subjects (44 in each group) will be enrolled in this&#xD;
      study.The aim of this clinical trial is to evaluate pharmacokinetic similarity between&#xD;
      recombinant monoclonal antibody against human epidermal growth factor receptor injection&#xD;
      (HS627) and Perjeta ® in a single intravenous infusion in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 13, 2020</start_date>
  <completion_date type="Actual">March 13, 2021</completion_date>
  <primary_completion_date type="Actual">February 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)0-∞</measure>
    <time_frame>150 days</time_frame>
    <description>Evaluation of Area under the plasma concentration versus time curve (AUC)0-∞</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)0-t</measure>
    <time_frame>150 days</time_frame>
    <description>Evaluation of Area under the plasma concentration versus time curve (AUC)0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>150 days</time_frame>
    <description>Evaluation of Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The total clearance(CL)</measure>
    <time_frame>150 days</time_frame>
    <description>Evaluation of the total clearance(CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>elimination half-life time(T1/2)</measure>
    <time_frame>150 days</time_frame>
    <description>Evaluation of elimination half-life time(T1/2)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Perjeta ®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)</intervention_name>
    <description>A single intravenous infusion of HS627 420mg</description>
    <arm_group_label>recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perjeta ®</intervention_name>
    <description>A single intravenous infusion of Perjeta ®420mg</description>
    <arm_group_label>Perjeta ®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male aged 18-40.&#xD;
&#xD;
          -  The body mass index is in the range of 19-26 kg/m2 (including thecritical value). The&#xD;
             weight is 50 kg-80kg.&#xD;
&#xD;
          -  The subjects have no family planning within 3 months and could select contraceptive&#xD;
             method&#xD;
&#xD;
          -  The subjects who have signed the informed consent and are able to complete the&#xD;
             experiment according to the trial protocol.&#xD;
&#xD;
          -  Echocardiography showed left ventricular ejection fraction (LVEF) &gt; 50% ,which two&#xD;
             weeks before administration of experimental drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subjects with a history of malignant tumor.&#xD;
&#xD;
          -  The subjects who has received any live vaccine within 6 months prior to signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  The subjects who has upper respiratory tract infection or other acute infections&#xD;
             within the previous 2 weeks of screening.&#xD;
&#xD;
          -  The subjects who had undergone surgery within 2 months prior to signing the informed&#xD;
             consent.&#xD;
&#xD;
          -  Anti-drug antibody (ADA) detection positive.&#xD;
&#xD;
          -  Previous treatment with any antibody targeting the HER2 receptor or Those who have&#xD;
             used monoclonal antibodies within 6 months prior to signing the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Phase I Clinical Research Center</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

